Aastrom Biosciences is dedicated to the development of treatments for critical cardiovascular diseases. Aastrom is currently evaluating its autologous cellular therapies in late-stage U.S. clinical trials in the treatment of critical limb ischemia (CLI) and dilated cardiomyopathy (DCM). These critical diseases are associated with significant morbidity and mortality and very limited treatment options.

Recent Milestones
edit

Aastrom Biosciences received $40M in Venture Round funding. (3/9/12)

Posted 3/12/12 at 7:47pm via yahoo.com
Aastrom Biosciences added Tim Mayleben as CEO / President / Director. (12/1/09)

Posted 5/25/13 at 10:07pm
Aastrom Biosciences added Timothy M. Mayleben as Chief Executive Officer, President, and Director.

Posted 3/12/12 at 7:49pm
Aastrom Biosciences added Ronnda L. Bartel as Chief Scientific Officer.

Posted 3/12/12 at 7:49pm